PUBLIC COMPANY
save$NRIXNurix Therapeutics, Inc.
$NRIX23.67+2.87%Brisbane, CA, USupdated 1d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- phase1A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- phase2Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
- phase3Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- phase1A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
- phase1Relative Bioavailability of NX-5948 Tablets vs Capsules and the Effect of Covariates on the PK of NX-5948 Tablets
- phase1A Study of NX-1607 in Adults With Advanced Malignancies
- phase1A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects
🐶 Hiring Signal
next earnings Oct 8, 2026
Where Nurix Therapeutics, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 31
News
- 11 companies hiring in California nowLooking for a biopharma job in California? Check out the BioSpace list of 11 companies hiring life sciences professionals like you.biospace · 19d ago
Data sources
last refreshed 57m ago
Found something off?
comments(0)
5-min edit window · permanent after that